Navigation Links
Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51

and exocrine pancreas, all of which are easily visualized. This screen allows quick validation of DNMT1 inhibition in vivo, as well as important data on the toxicity of compounds tested.

Abstract No. 3261

Discovery and development of MP529, a new effective and selective inhibitor of Aurora A kinase

MP529 series compounds, such as SGI-498, SGI-503, SGI-1097 and SGI-1215, demonstrate potent nanomolar inhibitory activity against the Aurora-A enzyme in biochemical enzyme-based assays, while exhibiting little to no activity versus the Aurora B kinase. SuperGen developed this series of lead compounds for use in anticancer therapy using rational-based drug design. Extensive in silico screening reduced the number of compounds submitted to physical assays to fewer than 100, saving significant time and resources over standard drug discovery practices. The series of compounds was evaluated in in vivo xenograft models and showed efficacy while maintaining desirable pharmacokinetic properties.

Abstract No. 5421

Dual inhibition of receptor tyrosine kinases of PDGFR and EGFR abolishes prostate cancer cell growth in culture and in a mouse xenograft model by complete dephosphorylation of PKB/Akt

MP470, SuperGen's multi-targeted tyrosine kinase inhibitor, in combination with Tarceva was more effective than either treatment alone in the inhibition of cell proliferation and phosphorylation of Akt in EGF and PDGF pathways. Moreover, in combination with Tarceva, MP470 inhibited Akt phosphorylation in LNCaP prostate cells. Finally, the MP470/Tarceva treatment was shown to abolish prostate tumor growth in an LNCaP xenograft mouse model

Mini-symposium Abstract No. 4142

Novel DNA hypomethylating agents: non-nucleoside compounds that do not incorporate into DNA selectively induce degradation of DNA methyltransferase I (DNMT1) in human cancer cells by the proteasomal pathway and re-express silenced tumor suppressor genes

Researche
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
2. AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer
3. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
4. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. NIEHS Researchers Identify Enzyme Critical in DNA Replication
7. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
8. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
9. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
10. Critical Therapeutics Announces the Publication of New Preclincial HMGB1 Data in Nature Immunology
11. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
Post Your Comments:
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/23/2015)... 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... the development and sale of patented biopharmaceutical medicine, modernized ... ingredients (API) today announced the business and development progress ... 1. Following the September 2014 JCM application (No. ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... Biopharmaceutical Services, Inc. announced today that the U.S. ... for an Electronic Submissions Gateway (ESG) to the ... clients a validated, direct electronic path for IND ... BLA (Biologic License Application) submissions and builds upon ...
... Gamma Knife® Perfexion™ earned the number one ranking in the ... in KLAS Awards: Medical Equipment & Infrastructure* report. Perfexion ... In the report, Perfexion scored 92.9 out of ... again. On a 1 to 9 scale, Perfexion received an ...
Cached Medicine Technology:Laureate's Electronic Submission Gateway Approved 2Elekta's Leksell Gamma Knife Perfexion is Ranked 2011's Best in KLAS for Radiation Therapy 2Elekta's Leksell Gamma Knife Perfexion is Ranked 2011's Best in KLAS for Radiation Therapy 3
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has been ... business is showing its latest designs of wedding dresses and ... the company’s CEO, all the fresh new products are designed ... up to 80% off. All the clothes from LunaDress follow ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in ... Player Health Alliance (PPHA). The PPHA's passion for others' ... including NFL greats, treated for obstructive sleep apnea (OSA) has ... the cause in the valley. The most recent plans for ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting ... . , Purchasing an accidental death and dismemberment rider ... type of rider provides benefits if the insured dies in ... lesser form of life insurance. , AD&D is not ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... website to improve navigation, functionality and user-friendliness. The new website ... but with better design and navigation, users can now access ... ... Neptune Beach, FL (PRWEB) May 18, ...
... Most Hispanics agree that the health of the entire ... their ownRIDGEFIELD, Conn., May 18 The economic downturn ... in the Hispanic community, with parents prioritizing their children,s ... Hispanics consider it equally important for parents to take ...
... States District Court issued a decision and order Friday ... attempt to prevent Ted Karkus, Mark Burnett, John ... McCubbin ("the Shareholder Nominees") from continuing their efforts to allow ... current board. The Federal Court,s decision followed ...
... /PRNewswire-Asia-FirstCall/ -- Emerald Dairy, Inc.,(OTC Bulletin Board: EMDY), a leading ... soybean products in China, today announced,results for the first fiscal ... Financial Highlights for the First Quarter, -- ... essentially breakeven in the ...
... on frequency of resistance development and safety presented ... and Infectious Diseases (ECCMID)SAN DIEGO, May 18 ... drugs for the treatment of serious bacterial infections, ... torezolid (TR-701), a novel antibiotic that is a ...
... Sciences, Inc. (OTC Bulletin Board: DSCI), a provider ... first quarter ended March 31, 2009. For the quarter, ... million in the first quarter 2008. The sales decrease of ... a significant weakening in the Canadian dollar and inventory rationalization ...
Cached Medicine News:Health News:International Student Insurance Announces Website Redesign 2Health News:New Research Finds Recession Has Greater Impact on Health of Parents than Children with Specific Findings on Hispanics 2Health News:New Research Finds Recession Has Greater Impact on Health of Parents than Children with Specific Findings on Hispanics 3Health News:Judge Rejects Quigley's Claims - Karkus Director Candidates Prevail in Federal Court 2Health News:Judge Rejects Quigley's Claims - Karkus Director Candidates Prevail in Federal Court 3Health News:Judge Rejects Quigley's Claims - Karkus Director Candidates Prevail in Federal Court 4Health News:Judge Rejects Quigley's Claims - Karkus Director Candidates Prevail in Federal Court 5Health News:Judge Rejects Quigley's Claims - Karkus Director Candidates Prevail in Federal Court 6Health News:Judge Rejects Quigley's Claims - Karkus Director Candidates Prevail in Federal Court 7Health News:Emerald Dairy Inc. Reports Record Earnings For First Quarter 2009 2Health News:Emerald Dairy Inc. Reports Record Earnings For First Quarter 2009 3Health News:Emerald Dairy Inc. Reports Record Earnings For First Quarter 2009 4Health News:Emerald Dairy Inc. Reports Record Earnings For First Quarter 2009 5Health News:Emerald Dairy Inc. Reports Record Earnings For First Quarter 2009 6Health News:Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 2Health News:Derma Sciences Reports First Quarter 2009 Results 2Health News:Derma Sciences Reports First Quarter 2009 Results 3Health News:Derma Sciences Reports First Quarter 2009 Results 4Health News:Derma Sciences Reports First Quarter 2009 Results 5Health News:Derma Sciences Reports First Quarter 2009 Results 6
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: